Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy. Its first CAR therapy will be tested in patients with ovarian cancer. ... priming a T-cell response – and may be more efficient than CAR-Ts at penetrating into the depths of tumours.

Latest news

More from news
Approximately 5 fully matching, plus 190 partially matching documents found.

Latest Intelligence

  • The NHS and ABPI at 70: inching closer to the triple win The NHS and ABPI at 70: inching closer to the triple win

    Meanwhile, the pharma industry is hitting new heights in drug innovation, including cures for diseases such as hepatitis C, haemophilia and huge progress in cancer and cell and gene therapy - but ... This, and near-perpetual reform, continues to confound

  • No incentive for a cure No incentive for a cure

    Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83%

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • A unique ecosystem A unique ecosystem

    Regenerative medicine aims to repair injuries or diseased organs using biomaterials, gene therapy, cell therapy and tissue engineering.

More from intelligence
Approximately 1 fully matching, plus 27 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

  • Celgene boosts CAR-T stake again with Bluebird Bio deal Celgene boosts CAR-T stake again with Bluebird Bio deal

    Mere weeks after completing its acquisition of CAR-T specialist Juno, Celgene has added to its cell therapy pipeline with another clinical-stage CAR-T candidate from Bluebird Bio. ... well as a pipeline of other cell and gene therapy candidates.

  • Bone Therapeutics strengthens board with new chairman Bone Therapeutics strengthens board with new chairman

    Bone Therapeutics strengthens board with new chairman. Jean Stéphenne joins the cell therapy company from TiGenix. ... He will be a valuable addition to an already strong board as we advance our allogeneic cell therapy platform through clinical

  • Zelluna appoints Miguel Forte as CEO Zelluna appoints Miguel Forte as CEO

    Forte’s expertise is predominantly in regenerative medicine, cell therapy, medical and regulatory affairs industries and is currently chief commercialisation officer and chair of the commercialisation committee for the International Society

More from appointments
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    Training the next generation of biotech leaders. Cell and gene therapy is no longer science fiction. ... As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy.

  • How do you define a biotech company?

    ReNeuron, a leading, clinical-stage stem cell business.

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    stem cell therapy and to learn his perspective on navigating the challenges that come with developing products in this complex market. ... You have this fantastic jewel that nobody really noticed but in the end it’ s a major discovery – the PD1

  • Healthcare in the Digital Age

    Exciting developments in immunotherapy and oncology, and huge strides in gene and stem-cell therapy are matched by powerhouse collaborations between academia and industry that point to a golden age for

  • Marketing strategy in complex environments

    disease. Whilst not new, this approach is becoming increasingly effective for certain therapy areas, particularly  oncology. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving the

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics